A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
This study is being conducted to demonstrate the superiority in progression-free survival (PFS) of dinaciclib compared to ofatumumab in chronic lymphocytic leukemia (CLL) participants with del 17p or in the overall population who are refractory to either fludarabine treatment or chemoimmunotherapy.
Chronic Lymphocytic Leukemia (CLL)
DRUG: Dinaciclib|DRUG: Ofatumumab
Participant Progression Free Survival, From date of randomization up to approximately 38 months
Participant Overall Response Rate, From date of randomization up to approximately 38 months|Participant Overall Survival Rate, From date of randomization until up to approximately 50 months
Dinaciclib is a cyclin-dependent kinase (CDK) inhibitor, specific for CDK 1, 2, 5 and 9.